Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 5:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 2,634 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Intermediate dose Clear all
Active, not recruiting Phase 2 Interventional

Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)

NCT05130827
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Plinabulin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 27, 2026, 5:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug-Drug Interaction Between Colchicine and Verapamil ER

NCT00983242
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Colchicine, Verapamil HCl ER
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
East Grand Forks, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 15, 2009 · Synced Oct 27, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Results available

Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer

NCT00595088
View directory record Official record
Conditions
Superficial Bladder Cancer
Interventions
BC-819/PEI
Biological
Lead sponsor
Anchiano Therapeutics Israel Ltd.
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Oct 27, 2026, 5:38 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma

NCT03030261
View directory record Official record
Conditions
Multiple Myeloma in Relapse
Interventions
Elotuzumab, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
2
States / cities
Denver, Colorado • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 27, 2026, 5:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate Pharmacokinetics of Prototype Modified-Release Formulations Of Apremilast in Healthy Men

NCT02236988
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Apremilast Immediate Release, Apremilast Modified Release 1, Apremilast Modified Release 2, Apremilast Modified Release 3, Apremilast Modified Release 4, Apremilast Modified Release 5, Apremilast Modified Release 6, Apremilast Modified Release 8, Apremilast Modified Release 9, Apremilast Modified Release 11, Apremilast Modified Release 12, Apremilast Modified Release 13, Apremilast Modified Release 14
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Oct 27, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Results available

APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers

NCT03165994
View directory record Official record
Conditions
Esophageal Cancer, GastroEsophageal Cancer
Interventions
APX005M, Radiation Therapy, Paclitaxel, Carboplatin, Surgical resection of tumor
Drug · Radiation · Procedure
Lead sponsor
Apexigen America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
10
States / cities
Tucson, Arizona • Duarte, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Oct 27, 2026, 5:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Cross-over Study Examining the Bioequivalence of 3 Test Formulations to a Reference Formulation of Alectinib (RO5424802) in Healthy Volunteers

NCT02074553
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Ro542-4802/F03 (Reference), Ro542-4802/F07 (Test), Ro542-4802/F08 (Test), Ro542-4802/F14 (Test)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Oct 27, 2026, 5:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety and Tolerability of E2511 in Healthy Participants

NCT04547361
View directory record Official record
Conditions
Healthy Volunteers
Interventions
E2511, E2511 Matched Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Oct 27, 2026, 5:38 PM EDT
Terminated No phase listed Observational

Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy

NCT03393741
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms
Interventions
Taxane, Vinorelbine, Ixabepilone, Eribulin, Chemotherapy
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Oct 27, 2026, 5:38 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Split-face Tolerability Comparison Between MetroGel® 1% vs Finacea® 15% in Subjects With Healthy Skin

NCT01139047
View directory record Official record
Conditions
Skin Manifestations
Interventions
metronidazole 1% gel, azelaic acid 15% gel
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Colorado Springs, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Oct 27, 2026, 5:38 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS

NCT02488408
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
Bemcentinib, Cytarabine, Decitabine
Drug
Lead sponsor
BerGenBio ASA
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
2
States / cities
Iowa City, Iowa • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Oct 27, 2026, 5:38 PM EDT
Active, not recruiting Phase 1 Interventional

Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung Cancer

NCT03223155
View directory record Official record
Conditions
Stage IV Small Cell Lung Cancer
Interventions
Nivolumab, Ipilimumab, Stereotactic body radiation therapy
Drug · Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 27, 2026, 5:38 PM EDT
Recruiting Phase 2 Interventional

Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma

NCT04318717
View directory record Official record
Conditions
Mucosal Melanoma of the Head and Neck
Interventions
Pembrolizumab, Hypofractionated radiation therapy
Drug · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
16 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2032
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 27, 2026, 5:38 PM EDT
Completed No phase listed Observational

Impact of Opioid Avoidance Protocol for ACL Reconstruction

NCT06340932
View directory record Official record
Conditions
ACL Tear, Post Operative Pain
Interventions
Iovera, Celecoxib, Acetaminophen, Oxycodone, Tramadol, Bupivacaine Hydrochloride, Acetaminophen 500Mg Cap
Device · Drug
Lead sponsor
Matthew Varacallo
Other
Eligibility
15 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
DuBois, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 27, 2026, 5:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effects of Itraconazole on MK-1708 in Healthy Participants (MK-1708-003)

NCT06586606
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
MK-1708, Itraconazole
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 27, 2026, 5:38 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

The Diabetes Prevention Trial of Type 1 Diabetes (DPT-1)

NCT00004984
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Parenteral Insulin, Close Observation, Oral Insulin, Placebo
Drug · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
3 Years to 45 Years
Enrollment
711 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1994 – 2003
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2020 · Synced Oct 27, 2026, 5:38 PM EDT
Completed No phase listed Observational

Fluoroquinolone Associated Disability

NCT03535558
View directory record Official record
Conditions
Bronchitis, Sinusitis, Urinary Tract Infections
Interventions
Fluoroquinolone (FQ), Azithromycin (AZ), Sulfamethoxazole/Trimethoprim (ST) Fixed Dose Combination
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
239,306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Titusville, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Oct 27, 2026, 5:38 PM EDT
Not listed Not applicable Interventional

Immunosuppression Management in Renal Transplant Recipients With Transplant Excellence Based on TruGraf Test

NCT04670926
View directory record Official record
Conditions
Kidney Transplant Rejection, Immunosuppression
Interventions
TruGraf, Standard of Care
Diagnostic Test · Other
Lead sponsor
Transplant Genomics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2021 · Synced Oct 27, 2026, 5:38 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About How Food Affects the Uptake of Study Medicine Prifetrastat Into the Blood in Healthy Adults

NCT07731100
View directory record Official record
Conditions
Healthy Adults
Interventions
Prifetrastat
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 27, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Results available

A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia

NCT01350947
View directory record Official record
Conditions
Chronic Myelomonocytic Leukemia
Interventions
5-Azacitidine
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
3
States / cities
Buffalo, New York • Portland, Oregon • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 13, 2016 · Synced Oct 27, 2026, 5:38 PM EDT
Terminated Phase 1 Interventional

Safety and Efficacy of HMI-103 in Participants With Classical PKU Due to PAH Deficiency

NCT05222178
View directory record Official record
Conditions
Phenylketonurias, PAH Deficiency, Phenylketonuria
Interventions
HMI-103
Drug
Lead sponsor
Homology Medicines, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Topeka, Indiana • Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 27, 2026, 5:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of SIAN Nasal Spray in Healthy Adults

NCT05194358
View directory record Official record
Conditions
Cyanide Poisoning
Interventions
Stabilized Isoamyl Nitrite (SIAN)
Drug
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 45 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
Knoxville, Tennessee • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 27, 2026, 5:38 PM EDT
Not listed Phase 3 Interventional

Open-Label Duloxetine Monotherapy in the Treatment of Posttraumatic Stress Disorder

NCT00583193
View directory record Official record
Conditions
Posttraumatic Stress Disorders
Interventions
Duloxetine hydrochloride
Drug
Lead sponsor
Canive, Jose M., M.D.
Individual
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Dec 31, 2007 · Synced Oct 27, 2026, 5:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

To Investigate the Gastrointestinal Behaviour of Two Triple Combination Products in Healthy Male Volunteers

NCT03415243
View directory record Official record
Conditions
Common Cold
Interventions
Acetaminophen 650mg+Dextromethorphan 20mg+Phenylephrine 10mg, Acetaminophen 325mg+Dextromethorphan 10mg+Phenylephrine 5mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
21 Years to 45 Years · Male only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 24, 2019 · Synced Oct 27, 2026, 5:38 PM EDT